Payment overview · 2025
General Payments
$599.65
40 reported records · 8 companies
Healthcare provider profile · identity verified
Ramses Rojas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CAPE CORAL, FL · NPI 1194082859
Verified facts
What the public records show
CMS Open Payments records show Ramses Rojas, MD received $599.65 in general payments during 2025 across 40 reported records.
Amgen Inc. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $228.64 | 38.1% | 22 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $187.58 | 31.3% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $45.02 | 7.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.10 | 6.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $35.32 | 5.9% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $28.05 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.01 | 3.5% | 1 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $17.93 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $599.65 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $183.58 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $141.91 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $129.56 | 15 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $86.73 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.02 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $35.32 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $28.05 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $4.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
112 | 26 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 756 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 686 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 658 | 194 |
| Pantoprazole Sodium | Pantoprazole Sodium | 423 | 131 |
| Losartan Potassium | Losartan Potassium | 407 | 111 |
| Lisinopril | Lisinopril | 390 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 356 | 101 |
| Alprazolam | Alprazolam | 316 | 88 |
| Omeprazole | Omeprazole | 312 | 93 |
| Metformin Hcl | Metformin Hcl | 311 | 87 |
| Simvastatin | Simvastatin | 308 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 89 |
| Gabapentin | Gabapentin | 286 | 91 |
| Tramadol Hcl | Tramadol Hcl | 212 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 199 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 57 |
| Allopurinol | Allopurinol | 162 | 45 |
| Meloxicam | Meloxicam | 155 | 50 |
| Montelukast Sodium | Montelukast Sodium | 155 | 47 |
| Famotidine | Famotidine | 154 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 40 |
| Glimepiride | Glimepiride | 141 | 41 |
| Ozempic | Semaglutide | 138 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 129 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 34 |
| Alendronate Sodium | Alendronate Sodium | 116 | 32 |
| Celecoxib | Celecoxib | 116 | 43 |
| Synthroid | Levothyroxine Sodium | 112 | 26 |
| Carvedilol | Carvedilol | 111 | 34 |
| Farxiga | Dapagliflozin Propanediol | 110 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 45 |
| Metformin Hcl Er | Metformin Hcl | 109 | 34 |
| Eliquis | Apixaban | 108 | 29 |
| Trazodone Hcl | Trazodone Hcl | 108 | 34 |
| Furosemide | Furosemide | 103 | 34 |
| Lorazepam | Lorazepam | 101 | 25 |
| Ezetimibe | Ezetimibe | 100 | 34 |
| Sertraline Hcl | Sertraline Hcl | 98 | 29 |
| Atenolol | Atenolol | 96 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 67 |
| Glipizide Er | Glipizide | 80 | 22 |
| Prednisone | Prednisone | 77 | 51 |
| Doxycycline Hyclate | Doxycycline Hyclate | 76 | 61 |
| Torsemide | Torsemide | 76 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 33 |
| Clonazepam | Clonazepam | 72 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | 17 |
| Pregabalin | Pregabalin | 71 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 28 |
| Donepezil Hcl | Donepezil Hcl | 70 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 38 |
| Lovastatin | Lovastatin | 68 | 17 |
| Bupropion Xl | Bupropion Hcl | 67 | 17 |
| Mounjaro | Tirzepatide | 67 | 16 |
| Fenofibrate | Fenofibrate | 61 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 22 |
| Potassium Chloride | Potassium Chloride | 60 | 18 |
| Irbesartan | Irbesartan | 56 | 15 |
| Jardiance | Empagliflozin | 56 | 21 |
| Repatha Sureclick | Evolocumab | 56 | 16 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 54 | 26 |
| Xarelto | Rivaroxaban | 53 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 13 |
| Temazepam | Temazepam | 49 | 17 |
| Valsartan | Valsartan | 49 | 17 |
| Trulicity | Dulaglutide | 48 | 14 |
| Estradiol | Estradiol | 47 | 15 |
| Spironolactone | Spironolactone | 47 | 14 |
| Buspirone Hcl | Buspirone Hcl | 46 | 17 |
| Finasteride | Finasteride | 46 | 13 |
| Glipizide | Glipizide | 46 | 13 |
| Ibuprofen | Ibuprofen | 46 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 12 |
| Diazepam | Diazepam | 41 | 20 |
| Mupirocin | Mupirocin | 39 | 35 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | 12 |
| Benazepril Hcl | Benazepril Hcl | 37 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 35 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Linzess | Linaclotide | 34 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 11 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 12 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 23 |
| Methylprednisolone | Methylprednisolone | 31 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 12 |
| Naproxen | Naproxen | 29 | 14 |
| Xtampza Er | Oxycodone Myristate | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 26 |
| Meclizine Hcl | Meclizine Hcl | 28 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Prolia | Denosumab | 28 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Lactulose | Lactulose | 22 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Ciclopirox | Ciclopirox | 21 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | 12 |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 13 |
| Gemtesa | Vibegron | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $599.65 · 40 records | Amgen Inc. | EVENITY, Evoke, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, INSPIRE, OTEZLA, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Wegovy, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error